ADVAXIS INC. overview

Kahn Swick & Foti, LLC and Monteverde & Associates PC announce that, on March 28, 2022, Advaxis, Inc. issued a Supplemental Proxy Statement that includes additional clarifying information about how to vote regarding Proposal No. 1 (the Reverse Stock Split), which will be voted on at the Special Meeting of Stockholders scheduled for March 31, 2022. We urge shareholders to review the Supplemental Proxy Statement. Information about it is located here:...

OTC Markets Group Welcomes Advaxis, Inc. to OTCQX PR Newswire NEW YORK, Dec. 23, 2021 NEW YORK , Dec. 23, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for over 11,000 U.S. and global securities, today announced Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company, has qualified to trade on the OTCQX® Best Market. Advaxis, Inc. previously traded on NASDAQ. Advaxis, Inc. begins trading today on OTCQX under the symbol "ADXS." U.S....

Thinking about buying stock in Zomedica, Advaxis, Kaixin Auto, SelectQuote, or Coty? PR Newswire NEW YORK, Aug. 26, 2021 NEW YORK , Aug. 26, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, ADXS, KXIN, SLQT, and COTY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ZOM:...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Advaxis, Inc. - ADXS PR Newswire NEW YORK, July 16, 2021 NEW YORK , July 16, 2021 /PRNewswire/-- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City , is investigating Advaxis, Inc. ("ADXS" or the "Company") ( ADXS ) relating to its...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Advaxis, Inc. (NasdaqGS: ADXS) (“the Company”) with Biosight Ltd. pursuant to which Advaxis shareholders will own approximately 25% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company. If you believe that this transaction...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Advaxis, Inc. PR Newswire NEW YORK, July 6, 2021 NEW YORK , July 6, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS) in connection with the proposed merger of the Company with privately-held pharmaceutical development company, Biosight Ltd. ("Biosight"). Under the terms of the merger agreement,...

...